

## Managed Care Interventions for Improving Outcomes in Acute Heart Failure Syndromes

This supplement to *The American Journal of Managed Care* provides information on the diagnosis and management of acute heart failure syndromes. Novel managed care interventions to improve the quality of care for acute heart failure syndromes and manage the financial burden of the disease are discussed.

### Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

### ■ Faculty

#### **Jeffrey D. Dunn, PharmD, MBA**

Formulary and Contracts Manager  
SelectHealth Plans  
Salt Lake City, Utah

#### **Gregg C. Fonarow, MD, FAHA, FACC**

Professor of Cardiovascular Medicine  
Associate Chief, Division of Cardiology  
Geffen School of Medicine at UCLA  
Los Angeles, California

#### **Mihai Gheorghiade, MD, FACC**

Professor of Medicine and Surgery  
Associate Chief, Division of Cardiology  
Northwestern University  
Feinberg School of Medicine  
Chicago, Illinois

#### **Sadiya Sana Khan, BS**

Division of Cardiology  
Northwestern University  
Feinberg School of Medicine  
Chicago, Illinois

#### **Ed Pezalla, MD, MPH**

National Medical Director, Pharmacy Management  
Aetna Pharmacy Management  
Hartford, Connecticut

## ■ Faculty Disclosures

The faculty has reported the following:

### **Gregg C. Fonarow, MD, FAHA, FACC**

*Research grants:* GlaxoSmithKline, Medtronic, National Institutes of Health, Novartis

*Consultant and Honoraria:* GlaxoSmithKline, Medtronic, Novartis, Pfizer, Scios

### **Mihai Gheorghiad, MD, FACC**

*Research grants:* Merck, National Institutes of Health, Otsuka, Scios Inc, Sigma Tau

*Consultant:* Debbio Pharm, Errekappa Terapeutici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Protein Design Labs, Solvay

*Honoraria:* Abbott, AstraZeneca, GlaxoSmithKline, Medtronic, Otsuka, Protein Design Labs, Scios Inc, Sigma Tau

**Jeffrey D. Dunn, PharmD, MBA, Ed Pezalla, MD, MPH, and Sadiya Sana Khan, BS,** report no financial interest/relationship relating to the topic of this activity.

## ■ Planners and Managers

The *planners and managers* reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

**Steve Casebeer** (Impact Education, LLC)

**Alicia Rybovic** (*Pharmacy Times* Office of Continuing Professional Education)

**Kay Weigand** (University of Cincinnati)

### **Disclosure of Unlabeled Use**

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Cincinnati, *Pharmacy Times*, Impact Education, LLC, and Otsuka America Pharmaceutical, Inc, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati, *Pharmacy Times*, Impact Education, LLC, or Otsuka America Pharmaceutical, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

## **Physician Continuing Medical Education**

### **Accreditation Statement**

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Cincinnati and Impact Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

### **Credit Designation**

The University of Cincinnati designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

## **Pharmacist Continuing Education**

### **Accreditation Statement**

*Pharmacy Times* Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2.5 contact hours (0.25 CEUs) under the ACPE universal program number of 290-999-08-011-H01-P. This program is available for CE credit through December 31, 2009.